Potassium acetate, a new class 3 drug of HISCO, will enter the site for inspection

According to the website of the State Food and Drug Administration (CFDA), the three kinds of new drug potassium acetate of Hisilicon will enter the site for inspection, which means that the drug only needs to pass the inspection of production environment and production process, and is expected to be approved in the first half of next year Potassium acetate can supplement the potassium ion needed by human body, and is used to maintain the balance of body fluid composition and electrolyte According to the information from the State Food and drug administration, at present, there are no enterprises in China to produce the drug At the same time, Hengrui pharmaceutical, Kelun pharmaceutical, Shanxi Guorun pharmaceutical and Shenyang Pharmaceutical union technology apply for the drug Hisilicon is mainly engaged in the production and sales of chemical pharmaceutical preparations and APIs According to the information from the State Food and drug administration, Hisilicon has nearly 20 new drugs in application for production, involving parenteral and enteral nutrition drugs, dermatology, rheumatoid, endocrine and other fields.